RFA-CA-23-018: Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $600,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 10, 2023.
From the official notice on Grants.gov, last changed November 1, 2022. Checked November 7, 2026.
- Award ceiling$600,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsNot allowed
- Funded byNCI
- Median yearly award$909,872
- Typical project length5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-CA-23-018 were run by National Cancer Institute (NCI, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-23-018 in the NIH Guide.
Key dates
| Posted | October 31, 2022 |
|---|---|
| Deadline | January 10, 2023 |
| Archived by Grants.gov | February 15, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $909,872; it allows up to $600,000 per award.
- Most of the money in the 2 programs behind this notice (66% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this initiative is to establish an Academic-Industrial Partnership Program to develop new and/or validate existing technologies, methods, and assays for the capture and quantification of tumor associated cells, DNA, RNA, or exosomes in body fluids of patients with early stage disease or those at high risk; as well as distinguishing cancer from benign disease; or aggressive from indolent cancers. The precompetitive alliances with industry will harmonize and validate technologies, methods and assays associated with liquid biopsies.
Funded under RFA-CA-23-018 so far
NIH funded 5 projects under RFA-CA-23-018 in fiscal 2023 to 2026, at 4 institutions. The median yearly award was $909,872.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Multi-cancer early detection using cell-free DNA methylome analysis | University of California Los Angeles | 2026 | $529,619 |
| Expanding early cancer detection with high throughput OCEANA - Ovarian Cancer Exosome Analysis with Nanoplasmonic Array | Massachusetts General Hospital | 2026 | $941,221 |
| Multi-analyte Approach for Earlier Detection of Cancers in Non Plasma Biofluids | Johns Hopkins University | 2026 | $953,471 |
| EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer Assessment | University of California Los Angeles | 2025 | $2.7 million |
| Multi-modal Liquid Biopsy Early Assessment of Breast Cancer, Pancreatic Cancer, and Multiple Myeloma | University of Southern California | 2025 | $2.1 million |
Who has won Cancer Biology Research grants before
From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 70 | $151 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 109 | $144 million |
| Sloan-Kettering Institute for Cancer Research | New York | 66 | $136 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 47 | $107 million |
| The Regents of the University of California, San Francisco | California | 64 | $95.5 million |
Who has won Cancer Detection and Diagnosis Research grants before
From fiscal 2021 to 2025, Cancer Detection and Diagnosis Research (93.394) awarded $2.7 billion across 1,944 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 56 | $114 million |
| Fred Hutchinson Cancer Center | Washington | 37 | $96.7 million |
| The Leland Stanford Junior University | California | 62 | $89.1 million |
| Sloan-Kettering Institute for Cancer Research | New York | 52 | $88.7 million |
| The Johns Hopkins University | Maryland | 63 | $86.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-23-018 still open?
No. It closed on January 10, 2023.
Who can apply for Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 Clinical Trial Not Allowed)?
Closed January 10, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $600,000 each.
Who has been funded under RFA-CA-23-018?
NIH RePORTER lists 5 projects funded under RFA-CA-23-018 in fiscal 2023 to 2026, at 4 institutions. The most were at University of California Los Angeles, Massachusetts General Hospital, Johns Hopkins University.
Who has won Cancer Detection and Diagnosis Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, Fred Hutchinson Cancer Center, The Leland Stanford Junior University. The program made 1,944 awards worth $2.7 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)